Completed PHASE3 INTERVENTIONAL 2-arm NCT00666185

Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis

A Phase 3, Randomized, Double-Blind, Comparative Trial of Micafungin Versus Fluconazole for the Treatment of Esophageal Candidiasis

Sponsor: Astellas Pharma Inc

Conditions Candidiasis, Oral

Interventions Fluconazole Micafungin

Updated 7 times since 2017 Last updated: Sep 17, 2014 Started: Aug 31, 2003 Primary completion: Feb 29, 2004 Completion: Feb 29, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00666185, this PHASE3 trial focuses on Candidiasis, Oral and remains completed. Sponsored by Astellas Pharma Inc, it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Astellas Pharma Inc

Data source: Astellas Pharma Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Abadia Uberaba, Brazil , Arcadia-Pretoria, South Africa , Barretos, Brazil , Bellville - Cape Town, South Africa , Belo Horizonte, Brazil , Bloemfontein, South Africa , Boqueirao - Santos, Brazil , Brits, South Africa , Campinas, Brazil , Cape Town, South Africa and 27 more locations